id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-327240-nohxk3y6	Muller, Matthew P.	Adverse Events Associated with High‐Dose Ribavirin: Evidence from the Toronto Outbreak of Severe Acute Respiratory Syndrome	2012-01-06		.txt	text/plain	4551	254	48	Logistic regression was used to evaluate the association between ribavirin use and each adverse event (progressive anemia, hypomagnesemia, hypocalcemia, bradycardia, transaminitis, and hyperamylasemia) after adjusting for SARS‐related prognostic factors and corticosteroid use. 11, 12 In Toronto, Ontario, Canada, most patients seen during the initial phase of the outbreak were treated with high-dose intravenous ribavirin, based on a protocol recommended for the treatment of hemorrhagic fever. [13] [14] [15] [16] Studies of the clinical efficacy of ribavirin in patients with SARS were inconclusive, 11, [17] [18] [19] [20] and significant adverse events were reported, including severe hemolysis. 27, 28 We report the frequency of adverse events in 183 patients treated with high-dose ribavirin during the Toronto SARS outbreak. Our finding that 57% of patients developed progressive anemia (largely associated with hemolysis) is substantially higher than the 9-19% rate seen in ribavirin-treated patients with hepatitis C but is consistent with the 49-73% reported in previous noncontrolled studies of ribavirin-related adverse events in patients with SARS.	./cache/cord-327240-nohxk3y6.txt	./txt/cord-327240-nohxk3y6.txt